Landsberg Bennett & Dubbaneh LLC Purchases 127 Shares of Merck & Co., Inc. (NYSE:MRK)

Landsberg Bennett & Dubbaneh LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK) by 0.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,073 shares of the company’s stock after buying an additional 127 shares during the period. Merck & Co., Inc. makes up about 1.0% of Landsberg Bennett & Dubbaneh LLC’s portfolio, making the stock its 26th biggest holding. Landsberg Bennett & Dubbaneh LLC’s holdings in Merck & Co., Inc. were worth $3,737,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in MRK. Nuveen Asset Management LLC boosted its stake in Merck & Co., Inc. by 6,517.4% during the second quarter. Nuveen Asset Management LLC now owns 24,307,332 shares of the company’s stock valued at $2,038,169,000 after buying an additional 23,940,007 shares during the last quarter. BlackRock Inc. boosted its stake in Merck & Co., Inc. by 2.3% during the second quarter. BlackRock Inc. now owns 191,863,408 shares of the company’s stock valued at $16,087,745,000 after buying an additional 4,397,580 shares during the last quarter. FMR LLC boosted its stake in Merck & Co., Inc. by 41.2% during the first quarter. FMR LLC now owns 11,111,444 shares of the company’s stock valued at $924,139,000 after buying an additional 3,244,078 shares during the last quarter. Invesco Ltd. boosted its stake in Merck & Co., Inc. by 18.4% during the second quarter. Invesco Ltd. now owns 18,309,138 shares of the company’s stock valued at $1,535,222,000 after buying an additional 2,843,458 shares during the last quarter. Finally, Schroder Investment Management Group boosted its stake in Merck & Co., Inc. by 67.7% during the second quarter. Schroder Investment Management Group now owns 6,381,329 shares of the company’s stock valued at $535,075,000 after buying an additional 2,576,060 shares during the last quarter. 74.97% of the stock is owned by institutional investors.

In related news, EVP Richard R. Deluca sold 6,427 shares of the firm’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total transaction of $546,873.43. Following the completion of the sale, the executive vice president now directly owns 103,223 shares of the company’s stock, valued at approximately $8,783,245.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.27% of the stock is currently owned by company insiders.

Shares of NYSE:MRK traded up $0.58 during trading on Friday, hitting $84.34. The company had a trading volume of 5,944,308 shares, compared to its average volume of 8,180,964. The stock has a market cap of $213.25 billion, a price-to-earnings ratio of 19.43, a price-to-earnings-growth ratio of 1.69 and a beta of 0.53. Merck & Co., Inc. has a one year low of $66.10 and a one year high of $87.35. The company has a fifty day simple moving average of $84.58 and a two-hundred day simple moving average of $82.23. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.14. The business had revenue of $11.76 billion during the quarter, compared to analyst estimates of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the company earned $1.06 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 4.92 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 7th. Stockholders of record on Monday, September 16th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.61%. The ex-dividend date of this dividend was Friday, September 13th. Merck & Co., Inc.’s payout ratio is 50.69%.

MRK has been the subject of a number of research reports. Credit Suisse Group reissued a “buy” rating and set a $95.00 price target on shares of Merck & Co., Inc. in a research note on Wednesday, August 7th. Societe Generale set a $105.00 price target on Merck & Co., Inc. and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Svb Leerink initiated coverage on Merck & Co., Inc. in a research note on Friday, August 16th. They set an “outperform” rating and a $103.00 price target for the company. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $90.00 to $93.00 and gave the company an “overweight” rating in a research note on Friday, June 14th. Finally, Argus raised their price objective on Merck & Co., Inc. to $105.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and seventeen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $93.29.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: What is systematic risk?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.